18 and older, any sex, with Major Depressive Disorder or Depression. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Net Promoter Score, and Enrollment LikelihoodPrimary· 12 weeks
Study acceptability was indexed by participant-reported net-promoter scores. This is a response to a single question: "How likely would you be to recommend \[participation in a study or treatment like this\] to a friend or family member with depression?" Net promoter scores range from 0 (would not recommend) to 10 (would definitely recommend). Study acceptability was also indexed by an additional patient-reported metric, Enrollment Likelihood. Enrollment likelihood was a response to the question: "How likely would you be to enroll in this study given your experience in this study?" and respons
Net Promoter Score (0-10)
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
7.73
± 2.15
Sham Whole-body Hyperthermia (Sham Treatment)
8.00
± 2.08
Enrollment Likelihood (1-5)
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
4.13
± 1.06
Sham Whole-body Hyperthermia (Sham Treatment)
4.29
± 0.83
Change in Beck Depression Inventory-II (BDI-II)Secondary· Baseline and 12 weeks
Change in BDI-II from baseline assessment to final assessment. Scores range from 0 to 63 and items are summed to create a total score; higher scores indicate greater depression symptoms.
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
-19.07
± 2.69
Sham Whole-body Hyperthermia (Sham Treatment)
-21.10
± 2.41
Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS) 8a DepressionSecondary· Baseline and 12 weeks
Change in PROMIS8a Depression from baseline to final assessment. T scores are computed; higher scores indicate greater depression symptoms. A T-score of 60 indicates sub-clinical or elevated levels of depression. A T score of 50 indicates the population mean with a standard deviation of 10.
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
-10.79
± 2.66
Sham Whole-body Hyperthermia (Sham Treatment)
-11.54
± 2.84
Change in Hamilton Depression Rating Scale 6-item (HAMD-6) Self-ReportSecondary· Baseline and 12 weeks
Change in HAMD-6 from baseline to final assessment. Scores range from 0 to 22, and items are summed to create a total score; higher scores indicate greater depression symptoms.
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
-6.42
± 1.30
Sham Whole-body Hyperthermia (Sham Treatment)
-7.16
± 1.12
Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS) 4a AnxietySecondary· Baseline and 12 weeks
Change in PROMIS4a Anxiety from baseline to final assessment. T scores are computed; higher scores indicate greater depression symptoms. A T-score of 60 indicates sub-clinical or elevated levels of anxiety. A T score of 50 indicates the population mean with a standard deviation of 10.
Group
Value
95% CI
Active Whole-body Hyperthermia (Active Treatment)
-7.24
± 1.63
Sham Whole-body Hyperthermia (Sham Treatment)
-7.51
± 2.06
Adverse events — posted to ClinicalTrials.gov
Time frame: 12 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18 years or older with major depressive disorder (MDD).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06831708 — RCT of Short-Term Psychoanalytic vs. Cognitive Behavioral Therapy for GAD
· NA
· recruiting
NCT06768983 — Fatigue Reduction in Chronic Kidney Disease (CKD)
· NA
· completed
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC
· NA
· recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor
· Phase 2
· recruiting
NCT06749392 — An Individual-specific Synchrony Signature
· NA
· recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness
· NA
· recruiting
NCT07242105 — Optimizing Brain Excitability in Depression
· NA
· recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
NCT05284773 — Screening for Acute Malnutrition
· NA
· withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling
· NA
· not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M
· Phase 1, PHASE2
· not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans
· NA
· not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT)
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 30 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05708976.